A new "black cheque" company that claims to be the first in Europe devoted to biomanufacturing has been set up by a team of investors, including former Sanofi chief executive Gerard le Fur.
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and
Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to troubled Alzheimer's therapy
